Scientific discovery dossier · Experimental discoveries
SOCE_Score — research biomarker (neuroblastoma RNA-seq)
Prognostic implications of store-operated calcium entry signatures and immune dynamics in neuroblastoma via machine learning
- Record type
- Preclinical scientific discovery (not a clinical trial)
- Publication
- Peer-reviewed
- DOI
- 10.21037/tcr-2024-2563
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
- Scope / models
- Multiple / solid tumors — Nöroblastom RNA-seq veri kümeleri (çoklu kohort); cerrahi GI onkoloji kohortu değil
- Molecular mechanism
- SOCE-related gene-expression signature; statistical links to immune infiltration and prognosis are explored.
- Experimental models
- Multiple neuroblastoma RNA-seq datasets; claimed validation across cohorts; CMap drug-repurposing hypothesis.
- Translational distance
- Not a GI surgical oncology standard. Must not be presented as an approved predictive test. Needs medical review.
- Research biomarker
- SOCE_Score (transkriptomik imza)
For patients
What is being studied? Researchers studied calcium-related gene signatures in childhood neuroblastoma datasets. This is not a ready-made hospital test.
Why promising? Suggested SOCE biology may yield a measurable immune–prognostic signature; generates translational hypotheses.
What is not proven? Changing surgical oncology decisions; prospective randomized benefit; generalization to other cancers; licensed lab test status.
Is this standard care today? No — this is a laboratory/scientific discovery dossier, not a treatment option.
For clinicians
DOI 10.21037/tcr-2024-2563. Population: neuroblastoma. Do not label SOCE_Score as a colon/pancreas predictor — clinician review required.
Limitations: Pediatrik nöroblastom; GI cerrahi endikasyon yok; ML skoru klinik validasyon bekler.